(56) reported a case of NSCLC with EGFR L858R mutation, where increased c-MET protein expression was detected after resistance to gefitinib treatment without MET gene amplification or mutation, indicating resistance to gefitinib due to c-MET protein overexpression. This evidence concerns the gene MET and non-small cell lung carcinoma.